证券日报网讯爱美客（300896）9月11日在互动平台回答投资者提问时表示，截至2025年9月10日，公司 股东人数为54，575户。 ...

北京海润天睿律师事务所 关于爱美客技术发展股份有限公司 北京海润天睿律师事务所 关于爱美客技术发展股份有限公司 2025 年第二次临时股东大会的法律意见书 致：爱美客技术发展股份有限公司 北京海润天睿律师事务所（以下简称"本所"）接受爱美客技术发展股份有 限公司（以下简称"公司"）的委托，指派律师潘仙、张阳出席公司 2025 年第 二次临时股东大会，并依据《中华人民共和国公司法》（以下简称"《公司法》"）、 《上市公司治理准则》（以下简称"《治理准则》"）等法律法规、规范性文件 及《爱美客技术发展股份有限公司章程》（以下简称"《公司章程》"）的有关 规定，对本次股东大会相关事项依法进行见证并发表法律意见。 为出具本法律意见书，本所律师出席了公司本次股东大会，审查了公司提供 的召开本次股东大会的有关文件。公司已向本所及本所律师承诺，其所提供的文 件和所作的陈述、说明是完整、真实和有效的，无任何隐瞒、遗漏，并据此出具 法律意见。 2025 年第二次临时股东大会的法律意见书 中国·北京 北京市朝阳区建外大街甲 14 号广播大厦 5&9&10&13&17 层 邮编:100022 电话：(010)65219696 传真 ...

证券代码：300896 证券简称：爱美客 公告编号：2025-038 号 爱美客技术发展股份有限公司 2025 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会没有出现否决议案的情形； 一、会议召开和出席情况 （一）会议召开情况 1、会议通知： （1）公司董事会于 2025 年 8 月 19 日在中国证监会指定的创业板信息披露 网站巨潮资讯网（www.cninfo.com.cn）上刊登了《关于召开 2025 年第二次临时 股东大会的通知》（公告编号：2025-036）。 2、会议召开时间： 2、本次股东大会不涉及变更以往股东大会已通过的决议。 4、会议召开地点：北京市平谷区马坊工业园区金平西路 20 号院爱美客大厦 1 层会议室 1 5、会议召集人：公司董事会 6、会议主持人：公司董事长简军女士 本次股东大会的召集程序符合有关法律、行政法规、部门规章、规范性文件、 深圳证券交易所业务规则和《公司章程》等有关规定。 （1）现场会议召开时间：2025 年 9 月 11 日 15:00 （2）网络投票时间：通 ...

Market Performance - The medical beauty sector rose by 2.11% on September 11, with Ai Meike leading the gains [1] - The Shanghai Composite Index closed at 3875.31, up 1.65%, while the Shenzhen Component Index closed at 12979.89, up 3.36% [1] Individual Stock Performance - Ai Meike (300896) closed at 201.00, with a gain of 3.10% and a trading volume of 46,300 shares, amounting to a transaction value of 909 million yuan [1] - Huaxi Biological (688363) closed at 59.51, up 0.86%, with a trading volume of 47,500 shares, totaling 279 million yuan [1] - ST Meigu (000615) remained unchanged at 3.14, with a trading volume of 55,800 shares, amounting to 17.45 million yuan [1] - Jinbo Biological (832982) closed at 307.80, down 0.03%, with a trading volume of 7,759.81 shares, totaling 237 million yuan [1] Capital Flow Analysis - The medical beauty sector saw a net inflow of 35.23 million yuan from institutional investors, while retail investors experienced a net outflow of 45.10 million yuan [1] - Ai Meike had a net inflow of 35.43 million yuan from institutional investors, but a net outflow of 40.20 million yuan from retail investors [2] - Huaxi Biological experienced a net inflow of 1.46 million yuan from institutional investors, with a net outflow of 6.54 million yuan from retail investors [2] - ST Meigu had a net outflow of 1.66 million yuan from institutional investors, but a net inflow of 1.64 million yuan from retail investors [2]

Mergers and Acquisitions - Dongyangguang plans to jointly increase capital in Yichang Dongshu No.1 Investment Co., Ltd. with an associated party, with capital increases of 3.5 billion and 4 billion yuan respectively. The company intends to acquire 100% equity of Qinhuai Data's China operations through its wholly-owned subsidiary [1] - Aimeike has completed the acquisition of controlling interest in South Korea's REGEN Biotech, Inc., obtaining 59.5% equity after the completion of the transaction [2] - Longzi Co., Ltd. plans to acquire 67.5% equity of Chongqing Time through a cash payment of 92.475 million yuan [3] Shareholding Changes - Hongbai New Materials' controlling shareholder plans to reduce its stake by up to 3%, which includes a maximum of 6.5 million shares through centralized bidding and 13 million shares through block trading [4] - BYD executives and core personnel collectively increased their holdings by 488,200 shares, with a total investment of 52.3278 million yuan [5] - Sichuan Road and Bridge's controlling shareholder intends to reduce its stake by up to 2%, equating to a maximum of 17.4 million shares [6] Regulatory Issues - Baiyin Nonferrous Metals has received a notice from the China Securities Regulatory Commission regarding an investigation for suspected violations of information disclosure [7] - Huangting International's wholly-owned subsidiary's asset, the Crystal Island International Shopping Center, was put up for auction but ultimately failed to sell [8]

Mergers and Acquisitions - Dongyangguang plans to jointly increase capital in Yichang Dongshu No.1 Investment Co., Ltd. with an associated party, with capital increases of 3.5 billion and 4 billion yuan respectively. The company intends to acquire 100% equity of Qinhuai Data's China operations through its wholly-owned subsidiary Yichang Dongshu No.3 Investment Co., Ltd. [1] - Aimeike has completed the acquisition of controlling interest in South Korea's REGEN Biotech, Inc. Aimeike International now holds 85% of REGEN, translating to an actual ownership of 59.5% by Aimeike. [2] - Longzi Co., Ltd. plans to acquire 67.5% equity of Chongqing Milan Baiyu Time Aesthetic Medical Hospital Co., Ltd. for 92.475 million yuan. [3] Shareholding Changes - Hongbai New Materials' controlling shareholder plans to reduce its stake by up to 3%, which includes a maximum of 6.5 million shares through centralized bidding and 13 million shares through block trading. [4] - BYD executives and core personnel collectively increased their holdings by 488,200 shares of A-shares, with a total investment of 52.3278 million yuan. [5] - Sichuan Road and Bridge's controlling shareholder plans to reduce its stake by up to 2%, equating to a maximum of 17.4 million shares. [6]

Core Viewpoint - Aimei Ke's REGEN company has expanded its overseas product offerings, including AestheFill and PowerFill, and is experiencing steady production growth from its new factory in South Korea [1] Group 1 - REGEN company currently sells two products overseas: AestheFill and PowerFill [1] - The new factory in South Korea has been operational and is steadily increasing its production capacity [1]

Core Viewpoint - The company has successfully completed the acquisition of 85% of REGEN Biotech, Inc. for $190 million, enhancing its international market presence and future profitability [1] Group 1 - The acquisition was executed through the company's wholly-owned subsidiary, Aimeike Hong Kong, in collaboration with Aisheng Shourui (HK) Limited [1] - The transaction has been fully settled, resulting in the company obtaining a 59.5% stake in REGEN Biotech, Inc. [1] - This strategic move is expected to strengthen the company's core competitiveness and expand its international market reach [1]

证券代码：300896 证券简称：爱美客 公告编号：2025-037 号 爱美客技术发展股份有限公司 关于收购韩国 REGEN Biotech,Inc.公司控股权进展 暨交割完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、交易概述 截至 2025 年 6 月 30 日，标的公司已经完成董事会改选，爱美客国际公司作 为控股股东在标的公司董事会中拥有多数席位，已经实际控制标的公司的日常运 营。作为爱美客国际公司的控股股东，公司已能够控制标的公司，并已将其纳入 公司合并报表范围。具体内容详见公司于 2025 年 7 月 2 日在巨潮资讯网披露的 《关于收购韩国 REGEN Biotech,Inc.公司控股权进展的公告》。 2025 年 8 月 26 日，爱美客国际按股权收购协议的约定完成韩国 REGEN 项目 剩余 5%交易对价款的支付。 截至本公告日，爱美客国际已完成韩国 REGEN 项目 100％交易对价款的支付。 三、本次交割完成情况 截至 2025 年 9 月 10 日，本次收购韩国 REGEN 控股权项目已经完成交割。爱 美客国际已取得韩国 ...

Group 1 - The core viewpoint of the article is that the company Aimei Ke (爱美客) has confirmed that its REGEN subsidiary is currently selling products overseas, specifically AestheFill and PowerFill [2] - REGEN's new factory in South Korea has been steadily increasing its production output since it began operations [2]